Stephens & Co. Maintains Overweight Rating on Veracyte
Analyst Mason Carrico of Stephens & Co. has maintained an 'Overweight' (Buy) rating on Veracyte, Inc. while adjusting the price target.
Stocks · News reference
Guggenheim analyst Subbu Nambi has maintained a 'Buy' rating on Veracyte, Inc. while lowering the price target to $35.
Reference Details
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
Keep reading
Analyst Mason Carrico of Stephens & Co. has maintained an 'Overweight' (Buy) rating on Veracyte, Inc. while adjusting the price target.
Piper Sandler has maintained a Buy rating on Veracyte, Inc. while significantly reducing its price target for the company's stock.
UBS has revised its price target for Veracyte, Inc. to $35 from the previous $65 while maintaining a Buy rating on the stock.